Treatment of excessive and irregular menses by a procedure called virechan nd oral drug.

MANAGEMENT OF ASRIGDARA WITH VIRECHANA AND VASADI GHANAVATI : AN OPEN LABLLED RANDOMIZED COMPARATIVE CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011280

Enrollment

Registered

2018-01-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ASRIGDARA (EXCESSIVE BLEEDING PER VAGINALLY)

Interventions

Intervention1: GROUP A-VASADI GHANAVATI WITH VIRECHANA : in group A firstly virechana with trivrut avaleha will be given then after vasadi ghanavati will be given 2 tab 6 hourly in bleeding phase or

Eligibility

Inclusion criteria

Inclusion criteria: A.patients having any one or two of the following features like 1.excessive per vaginal bleeding, 2.prolonged duration bleeding, 3.inter-menstrual bleeding, 4.bleeding with heavy clots B.patients who are yogyafor virechana

Exclusion criteria

Exclusion criteria: 1.age below 18 and 50 years. 2.bleeding due to polyp, erosion, cancer & fibroid. 3.bleeding followed by abortion 4.bleeding from the site other than the uterus. 5.coagulation disorders. 6.suffering from malignancies, diabetes, venereal disease. 7.patients who are Ayogya for Virechana. 8.postmenopausal bleeding 9.Hb% <8

Design outcomes

Primary

Measure	Time frame
cure of asrigdaraTimepoint: 4 month	—

Secondary

Measure	Time frame
Relief in bleeding as compare to previousTimepoint: 4 months	—

Countries

India

Contacts

Public ContactPooja Chauhan

Institute for post graduate teaching and research in ayurveda

deilaxmipriya@yahoo.com9228198366

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026